The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Manila – 29 th May’06

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Disclaimer

Asia’s Share of the World GDP (at PPP in %) Year China 17% 9% 5% 5% 12% India 12% 8% 4% 3% 5% Japan 2% 3% 3% 8% 7% Rest of Asia 7% 5% 7% 9% 13% Total Asia 38% 25% 19% 25% 37% Source – WEF - was 59% in 1820 with India 16%, China 33%

1.India+84% 2.Pakistan+75% 3.Korea+54% 4.Philippines+39% 5.China+34% Stock Market Performance in Asia in 2005 Source: Rimes in GBP

Davos 2006 Source – FT

The Productivity Advantage India a usa Pharma view USA 1 chemist 1 chemist 70 h/week 50 h/week $ 800 monthly $ 12,000 monthly Better education x 1,3 Longer working time x 1,3 Lower cost x 20 Sources: IPHMR Conferences, New Delhi August 2004

 Europe - retirees grow faster than workers - fertility rates lower, only 600k new Germans in 2005  Japan - expansion of grey segment  USA - over 50’s 88m will grow to 118m (2020) - obesity will cap life expectancy  China - one child families - get older before becoming wealthy - labour costs will rise owing to labour shortage - South Guangdong province is short of 2m workers  India - will remain very young - 50% <25years, 65% <35 years - source of the extra needed global workforce The Ageing Advantage

 GDP World growth marginally less in 06 than 05 (+4.3%)  USA expansion at a slower growth than 05 (+3.6%) Euro zone – expected to perform better than USA  Asia : Japan – sustain current growth PRC – slightly slower growth to prevent hard landing India – increasing growth rate being talked up to 9%/10%  Chindia: 40% population, 8% economy India sentiment: Largest foreign affairs caucus in US Congress (180) China sentiment: 74,000 demonstrations reported in 2005 in China The Economic Growth Advantage

 The world has 793 billionaires  USA has 371 – almost half  India - 23 billionaires, UK has 24  China - 8 billionaires  Net worth of 40 richest Indians - $106 b  40 richest Chinese - $26b “2006 belongs to some of the emerging markets, and no country more than India” Source: Forbes The Billionaires Advantage

The R&D Investment Advantage Most attractive R&D Investment locations: 1. China 2. USA 3. India 4. Japan 5. UK Source – UNCTAD 2005

 Qualified Scientists & Engineers  Global India players with Alliances  English speaking  TRIPs compliant – first patent March 2006  IIT, IIM & other scientific institutions Source – UNCTAD 2005 The R&D Investment Advantage -reasons why India

 4 th largest reservoir of Scientific Manpower (2 nd largest English speaking)  3m graduates pa, 115k MSc Chemistry, 345k IT, USA 75k  Knowledge super power in the making  Lead by a Nuclear Scientist as President – remote sensing satellite technology, 1/6 countries  Diaspora network (25m across 120 countries)  In ancient days India invented the zero  US & Europe will not dominate Science, Maths, IT The Knowledge Advantage

The State of European Science Teaching Source – Royal Society of Chemistry, Policy Bulletin – Spring 2006 “This means that when pupils are in a science laboratory their experience is unsafe, unsatisfactory or uninspiring for 65% of the time. In addition, 13% of science classes are not taught in a laboratory at all” Laboratories in UK state schools:Closed UK University Excellent 5% Chemistry D epartments: Good 29% Dundee Kings Basic/uninspiring 41% Surrey Exeter Unsafe/unsatisfactory 25% Lancaster Queen Mary under review-Sussex

 34 News TV channels. Oldest 13 years old (NDTV)  5000 newspapers, circulation 17m. 12 with 1m copies each  200m daily readers. 21m new daily readers 2003/2005, +14% with 50% rural and 50% urban readership  Principal internet languages to become English, Chinese and Hindi  STD Kiosks converted to Internet Cafes. India to become the largest Internet market in 5-10 years  Indians are hungry for information Source: World Business , Larry Page (Google) zeitgeist conference may 2006 The Information Advantage

 Manufacturing growth - Chinese manufacturing +12% - India manufacturing +6.5%  Scope for improvement of Government Policies  Revitalization of agriculture - beyond milk (1 st globally), wheat (2 nd ), rice (2 rd )  More privatization – public sector not so buoyant  Further encouragement of R&D for Pharmaceuticals  Expand further the prosperous middle class of 300m The Potential for Improvement Advantage

 High quality healthcare, international standards  Patients from developed & developing countries  Growing privatization of hospitals, paperless hospitals  Analysis of serum samples from EU hospitals in India already  Low Costs: Thailand India - Open heart $14250 $ Hysterectomy $ 2012 $ Knee surgery $7000 $4500  Better access through Indian immigration & airports likely The Medical Tourism Advantage

$b 2001/ / / / / Q 2005 at $2b for the first time in India - But still only 10% of China or Singapore The FDI Advantage

$m Leading to even more Pharma R&D facilities and factories Source – Citigroup Investment by top 15 Indian Domestic Pharmaceutical Companies

Investment by foreign Pharma companies

 Microsoft Global Development Centre (GDCI)  Microsoft Global Services (MGSI)  Microsoft Global Technical Support Centre (GTSC)  Microsoft Systems Research (MSRI)  Microsoft India Development Centre (MIDC) Investment by Microsoft in India

A Global Strategic Asset for developed World Market businesses India

Leading Generic Companies Source : Company /Financial reports & presentations Annual Sales (US$ Millions)

Annual USA ANDA Filings Ranbaxy29 Sun22 Orchid18 Lupin14 DRL13 Cadilla12 Source: Pharmabiz 8 th Sept’ One in every four ANDAs filed by Indian Companies - Source: KPMG ANDAs p.a ranks in top 3 filers The Pharma Advantage - ANDAs

% % % % % % Source: Citigroup *DMF – Drug Master Files Q India alone 43% The Pharma Advantage – API’s Chindia filings USA DMF filings by India Source: Crisil

The Pharma Advantage Competitive Advantage – Aggressive Home Market

The Pharma Advantage Competitive Advantage - Cost of Manufacture Active Pharmaceuticals Facility, MohaliDosage Forms Facility, Paonta Sahib Highest number of FDA approved plants outside the US Exports ($m): % % 2010E 70% Source: IPA No. of FDA approved plants: Source: Crisil / IPA

The Pharma Advantage R&D I R&D III R&D II R&D IV Competitive Advantage - Cost of Innovation

Fundamental drivers of Generic growth - healthcare costs Total Healthcare Spending, % of GDP The collective healthcare bill for Ford, Chrysler & GM in 2006 will be > $12b Source: World Bank, DB Global Pharma Report Aug 2005, OECD Health Data 2005 (1) – 2002, UBS European Pharma Report, Sep 2005

Fundamental drivers of Generic growth - Demographics Source: World Bank, DB Global Pharma Report Aug 2005, OECD Health Data 2005 (1) – 2002, UBS European Pharma Report, Sep 2005 Estimated % of regional population over 60

Fundamental drivers of generic growth – Patent Expiries Source : Global Generic Drug Stocks Citigroup Smith Barney, September 2004, IMS Health : MIDAS, MAT June 2005 Revenues $Bn

$b USA W Europe 9 14 Japan 3 4 Rest of America 6 9 ROW Total Source: Frost & Sullivan “India could soon dominate the entire production chain for generics” IMS prediction No 4 Scrip April The Global Generic Market – growing everywhere

Ranbaxy Strategic Direction US $ 1 Bn US $ 5 Bn US $ 2 Bn Amongst the Top 5 generic Companies Significant income from proprietary products 2012 Growth through - Organic - Inorganic

Potential Downsides to the Indian Scenario

Potential downside – Asian Flu* *50% of world chickens bred in Asia

Potential downside – Oil prices* Source – BLS, ELA, The Conference Board *Chindia consumes 40% oil

Potential downside – Infrastructure A common view Source – FT

Potential downside – Counterfeit products from India -but not a global issue Origin of fake products seized in EU in 2004 Rank 1. China 2. Thailand 3. Hong Kong 4. Turkey 5. USA Source: FT Countries where fake pharma products seized in 2005 Rank 1. Russia 2. China 3. South Korea 4. Peru 5. Columbia Source: PSI 192,000 died from Counterfeit drugs in China in 2001 Source: IMS 27 th Feb’2006

Asia economic strength is returning to levels seen in the past Many advantages for India – particularly R&D India as a global strategic asset Some downsides - infrastructure The current feeling in India a turning point has been reached and an inflexion point has been passed Summary

“We have all grown up learning the story of the unfinished voyage of Christopher Columbus setting sail to reach India, he discovered America. I now invite the people of America to complete the Voyage of that great explorer” Manmohan Singh Prime Minister of India July 2005

Thank You